A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma
Status:
Withdrawn
Trial end date:
2021-02-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if using the radioactive tracer 89Zr-DFO-daratumumab with
PET/CT scans is a practical and effective way to view and monitor multiple myeloma in
participants before and during their treatment with daratumumab. We also want to see if
89Zr-DFO-daratumumab PET/CT scans can predict a participant's response to therapy, and if
they can better locate any leftover disease following treatment compared to the standard
imaging methods.